Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy

Schwartzkopff, B.; Fassbach, Michael; Pelzer, Beate; Brehm, Michael; Strauer, Bodo E.

doi:10.1016/s1388-9842(02)00092-2

Cited by 101 publications

(87 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reports of changes in MMPs and TIMPs in patients with heart failure are generally consistent; reports of the ability to predict outcome are not. In heart failure, MMP1, 198 MMP2, 199,200 MMP9 199,200 and TIMP-1, 198,199,[201][202][203] but not MMP3, 199 are reported as elevated. One large study has reported that MMP9 is not elevated in patients with heart failure after adjustment for other variables.…”

mentioning

confidence: 99%

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE)

Collinson

Gaze²,

Thokala³

et al. 2013

Health Technol Assess

View full text Add to dashboard Cite

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.hta.ac.uk/ This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 09/22/16. The contractual start date was in August 2010. The draft report began editorial review in February 2012 and was accepted for publication in June 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. Published by the NIHR Journals Library, produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk). Objectives: To test the diagnostic accuracy for detecting an acute myocardial infarction (AMI) using highly sensitive troponin assays and a range of new cardiac biomarkers of plaque destabilisation, myocardial ischaemia and necrosis; to test the prognostic accuracy for detecting adverse cardiac events using highly sensitive troponin assays and this range of new cardiac biomarkers; and to estimate the cost-effectiveness of using highly sensitive troponin assays or this range of new cardiac biomarkers instead of an admission and 10-to 12-hour troponin measurement. NIHR Journals LibraryDesign: Substudy of the point-of-care arm of the RATPAC (Randomised Assessment ...

show abstract

mentioning

confidence: 99%

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE)

Collinson

Gaze²,

Thokala³

et al. 2013

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…It is known that any imbalance between a collagenase and its endogenous inhibitor can lead to changes in the ECM, causing tissue remodelling. 5,6,10,14,18,21 In the present study, MMP-9 and TIMP-1 levels and the MMP-9/TIMP-1 ratio were increased in ICM patients compared with normal control subjects, suggesting that type I collagen degradation is higher than synthesis in ischaemic myocardium. In addition, ICTP, which is the metabolite of type I collagen degradation, was also significantly increased in patients compared with normal control subjects.…”

Section: Discussionmentioning

confidence: 46%

“…13 When the myocardium is in an ischaemic state, the structure of the collagen network and the ratios of the different types of collagen appear to change. 4,6 Human and animal studies have suggested that regulating the composition of ECM can provide new insights into the prevention of cardiac remodelling in ischaemia. [14][15][16] Invasive myocardial biopsy has been the gold standard for evaluating myocardial fibrosis and tissue repair.…”

Section: Discussionmentioning

confidence: 99%

“…However, noninvasive ways of assessing collagen metabolism (by measuring the biomarkers MMP and TIMP) have been developed and may replace myocardial biopsy. 6,10,11,[17][18][19] In the present study, MMP-9 and its inhibitor TIMP-1 were chosen as markers of collagen haemostasis in ischaemic myocardium. 20 Due to the antagonistic relationship between MMP-9 and TIMP-1, the ratio of MMP-9 to TIMP-1 can reflect MMP hydrolyzing ability and activity, and can also indirectly estimate the balance between collagen synthesis and degradation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Improvement in collagen metabolism after 12 weeks’ cardiac resynchronization therapy in patients with ischaemic cardiomyopathy

Zhou

et al. 2013

J Int Med Res

View full text Add to dashboard Cite

Objectives: To investigate the effects of cardiac resynchronization therapy (CRT) on collagen metabolism biomarkers and their relationship to cardiac function, in patients with ischaemic cardiomyopathy (ICM). Methods: Serum levels of matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP-9 (TIMP-1), carboxyterminal propeptide of type I procollagen (PICP) and carboxyterminal telopeptide of type I collagen (ICTP) were quantified before and after 12 weeks' treatment, in patients with ICM receiving CRT and standard medical therapy (CRT group) or standard medical therapy alone (non-CRT group), and in controls. Cardiac function was measured echocardiographically. Results: MMP-9, TIMP-1, ICTP and the MMP-9/TIMP-1 ratio were significantly higher, and the PICP/ICTP ratio significantly lower, in patients with ICM (n ¼ 27) compared with controls (n ¼ 20). After 12 weeks' treatment, MMP-9, TIMP-1, ICTP and the MMP-9/TIMP-1 ratio were significantly higher, and the PICP/ICTP ratio significantly lower, in the non-CRT group (n ¼ 15) compared with the CRT group (n ¼ 12). The PICP/ICTP ratio correlated positively with TIMP-1 and negatively with MMP-9. The early/atrial ratio and left ventricular ejection fraction correlated positively and negatively, respectively, with the MMP-9/TIMP-1 ratio. Echocardiographic measurements of cardiac function were significantly worse in patients with ICM compared with controls and improved significantly after treatment in the CRT group. Conclusions: In ICM, collagen degradation biomarkers were elevated and correlated positively with cardiac function. CRT partially reversed the deterioration in collagen metabolism and enhanced cardiac function.

show abstract

“…Thus, a progressive activation of MMPs results in degradation of the fibrillar collagen matrix, and can lead to increased LV wall thinning and LV enlargement [15]. Recent clinical reports have demonstrated alterations in both myocardial and circulating activities of MMPs in patients with DCM [16][17][18]. Spinale et al [18] have reported a decreased myocardial activity of the interstitial collagenase, or MMP-1, which degrades the fibrillar collagen such as collagen types I and III, as well as increased activities of gelatinases, or MMP-2 and MMP-9, in DCM.…”

Section: Discussionmentioning

confidence: 99%

Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy

Ohtsuka

Inoue

Hara

et al. 2005

European J of Heart Fail

View full text Add to dashboard Cite

Background and aims: It has been proven that a disturbance in angiogenesis contributes to the progression of myocardial interstitial fibrosis in idiopathic dilated cardiomyopathy (DCM). This study was designed to evaluate the relationship between serum activity of angiogenic factors and myocardial ultrasonic tissue characterization in patients with DCM. Methods and results:We studied 30 patients with DCM and 15 healthy control subjects. Serum levels of vascular endothelial growth factor (VEGF), interleukin (IL)-4 and IL-13 were measured using enzyme-linked immunosorbent assay. We determined calibrated myocardial integrated backscatter (IB) as the value of myocardial interstitial fibrosis using ultrasonic tissue characterization and also quantified the magnitude of cyclic variations in IB (CV-IB). Serum levels of VEGF and IL-13 were significantly higher in patients with DCM than in control subjects (both Pb0.05). Calibrated IB was significantly higher and CV-IB was markedly lower in patients with DCM than in control subjects (both Pb0.01). In patients with DCM, the levels of IL-13 significantly correlated with calibrated IB (r=0.520, P=0.018). In addition, there was a significant negative correlation between levels of VEGF and CV-IB (r=À0.611, P=0.007). Conclusion: The increase in serum VEGF and IL-13 may be closely related to alterations in myocardial texture in DCM.

show abstract

Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy

Cited by 101 publications

References 33 publications

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE)

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE)

Improvement in collagen metabolism after 12 weeks’ cardiac resynchronization therapy in patients with ischaemic cardiomyopathy

Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy

Contact Info

Product

Resources

About